Melanocyte Receptors: Clinical Implications and Therapeutic Relevance

Dermatologic Clinics

Volumn 25, Issue 4, 2007, Pages 541-557

  Carlson, J Andrew ^a   Linette, Gerald P ^b   Aplin, Andrew ^c   Ng, Bernard ^a   Slominski, Andrzej ^d  

^a Department of Pathology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI PROTEIN; ALPHA INTERMEDIN; ANTALARMIN; BETA INTERMEDIN; BLOCKING ANTIBODY; BOSENTAN; CELL RECEPTOR; COLECALCIFEROL; CORTICOTROPIN RELEASING FACTOR; ENDOTHELIN RECEPTOR; ERLOTINIB; FAS ANTIGEN; FAS LIGAND; FIBROBLAST GROWTH FACTOR; FRIZZLED PROTEIN; FRIZZLED PROTEIN 5; G PROTEIN COUPLED RECEPTOR; GAMMA INTERMEDIN; GEFITINIB; GLUTAMIC ACID; IMATINIB; JAGGED1; MELANOCYTE RECEPTOR; MELATONIN; PROOPIOMELANOCORTIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROCORTIN; VASCULOTROPIN; WNT5A PROTEIN;

CELL PROLIFERATION; CELL SURFACE; CYTOLOGY; HUMAN; MELANOCYTE; PRIORITY JOURNAL; REVIEW; SKIN PIGMENTATION;

ANTINEOPLASTIC AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOCYTES; MELANOMA; NEOPLASM METASTASIS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 34648846034     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.06.005     Document Type: Review

References (141)

1. Slominski A., Tobin D.J., Shibahara S., et al. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84 4 (2004) 1155-1228
2. Slominski A., Wortsman J., Plonka P.M., et al. Hair follicle pigmentation. J Invest Dermatol 124 1 (2005) 13-21
3. Holbrook K.A. Melanocytes in human embryonic skin and fetal skin: review and new findings. Pigment Cell Res 1 Suppl (1998) 6-17
4. Yoshida H., Kunisada T., Grimm T., et al. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Invest Dermatol Symp Proc 6 1 (2001) 1-5
5. Fleischman R.A., Saltman D.L., Stastny V., et al. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci U S A 88 23 (1991) 10885-10889
6. Christiansen J.H., Coles E.G., and Wilkinson D.G. Molecular control of neural crest formation, migration and differentiation. Curr Opin Cell Biol 12 6 (2000) 719-724
7. Weeraratna A.T., Jiang Y., Hostetter G., et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1 3 (2002) 279-288
8. Bachmann I.M., Straume O., Puntervoll H.E., et al. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11 24 Pt 1 (2005) 8606-8614
9. Kunisada T., Yamazaki H., and Hayashi S.I. Review: ligands for receptor tyrosine kinases expressed in the skin as environmental factors for melanocyte development. J Investig Dermatol Symp Proc 6 1 (2001) 6-9
10. Haass N.K., and Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10 2 (2005) 153-163
11. Slominski A., Paus R., and Schadendorf D. Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol 164 1 (1993) 103-120
12. Moriyama M., Osawa M., Mak S.S., et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol 173 3 (2006) 333-339
13. Berking C., Takemoto R., Satyamoorthy K., et al. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res 64 3 (2004) 807-811
14. Noonan F.P., Dudek J., Merlino G., et al. Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res 16 1 (2003) 16-25
15. Wood J.M., Jimbow K., Boissy R.E., et al. What's the use of generating melanin?. Exp Dermatol 8 2 (1999) 153-164
16. Slominski A., and Wortsman J. Neuroendocrinology of the skin. Endocr Rev 21 5 (2000) 457-487
17. Slominski A., Wortsman J., Luger T., et al. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80 3 (2000) 979-1020
18. Diepgen T.L., and Mahler V. The epidemiology of skin cancer. Br J Dermatol 146 Suppl 61 (2002) 1-6
19. Gilchrest B.A., Eller M.S., Geller A.C., et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 340 17 (1999) 1341-1348
20. Kennedy C., ter Huurne J., Berkhout M., et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117 2 (2001) 294-300
21. Carlson J.A., Slominski A., Linette G.P., et al. Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev Mol Diagn 3 2 (2003) 163-184
22. Slominski A., and Pawelek J. Animals under the sun: effects of ultraviolet radiation on mammalian skin. Clin Dermatol 16 4 (1998) 503-515
23. Han J., Kraft P., Colditz G.A., et al. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 119 8 (2006) 1976-1984
24. Rees J.L. The genetics of sun sensitivity in humans. Am J Hum Genet 75 5 (2004) 739-751
25. Hauser J.E., Kadekaro A.L., Kavanagh R.J., et al. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Res 19 4 (2006) 303-314
26. Kadekaro A.L., Wakamatsu K., Ito S., et al. Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 11 (2006) 2157-2173
27. Landi M.T., Bauer J., Pfeiffer R.M., et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313 5786 (2006) 521-522
28. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
29. Carlson J.A., Ross J.S., Slominski A., et al. Molecular diagnostics in melanoma. J Am Acad Dermatol 52 5 (2005) 743-775 [quiz: 775-8]
30. Slominski A., Wortsman J., Pisarchik A., et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J 15 10 (2001) 1678-1693
31. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3 8 (2003) 559-570
32. Sharpless E., and Chin L. The INK4a/ARF locus and melanoma. Oncogene 22 20 (2003) 3092-3098
33. Daniotti M., Oggionni M., Ranzani T., et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23 35 (2004) 5968-5977
34. Gorden A., Osman I., Gai W., et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63 14 (2003) 3955-3957
35. Grichnik J.M., Burch J.A., Schulteis R.D., et al. Melanoma, a tumor based on a mutant stem cell?. J Invest Dermatol 126 1 (2006) 142-153
36. Lahav R. Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol 49 2-3 (2005) 173-180
37. Goding C.R. Melanocyte development and malignant melanoma. Forum (Genova) 10 3 (2000) 176-187
38. Widlund H.R., and Fisher D.E. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22 20 (2003) 3035-3041
39. Wehrli P., Viard I., Bullani R., et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 115 2 (2000) 141-148
40. Bullani R.R., Wehrli P., Viard-Leveugle I., et al. Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res 12 3 (2002) 263-270
41. Gavi S., Shumay E., Wang H.Y., et al. G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab 17 2 (2006) 48-54
42. Slominski A., Fischer T.W., Zmijewski M.A., et al. On the role of melatonin in skin physiology and pathology. Endocrine 27 2 (2005) 137-148
43. Slominski A., Wortsman J., and Tobin D.J. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J 19 2 (2005) 176-194
44. Li S., Huang S., and Peng S.B. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 27 5 (2005) 1329-1339
45. Eves P.C., MacNeil S., and Haycock J.W. alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 27 2 (2006) 444-452
46. Slominski A., Ermak G., and Mihm M. ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab 81 7 (1996) 2746-2749
47. Hunt G., Donatien P.D., Lunec J., et al. Cultured human melanocytes respond to MSH peptides and ACTH. Pigment Cell Res 7 4 (1994) 217-221
48. Kauser S., Schallreuter K.U., Thody A.J., et al. Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol 120 6 (2003) 1073-1080
49. Manna S.K., Sarkar A., and Sreenivasan Y. Alpha-melanocyte-stimulating hormone down-regulates CXC receptors through activation of neutrophil elastase. Eur J Immunol 36 3 (2006) 754-769
50. Moustafa M., Szabo M., Ghanem G.E., et al. Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol 119 6 (2002) 1244-1253
51. Healy E. Melanocortin 1 receptor variants, pigmentation, and skin cancer susceptibility. Photodermatol Photoimmunol Photomed 20 6 (2004) 283-288
52. Abdel-Malek Z.A., Kadekaro A.L., Kavanagh R.J., et al. Melanoma prevention strategy based on using tetrapeptide {alpha}-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J 20 9 (2006) 1561-1563
53. Scott M.C., Wakamatsu K., Ito S., et al. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci 115 Pt 11 (2002) 2349-2355
54. Abdel-Malek Z., Scott M.C., Suzuki I., et al. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res 13 Suppl 8 (2000) 156-162
55. Getting S.J. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 111 1 (2006) 1-15
56. Weiner R.E., and Thakur M.L. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs 19 3 (2005) 145-163
57. McQuade P., Miao Y., Yoo J., et al. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem 48 8 (2005) 2985-2992
58. Slominski A., Zbytek B., Pisarchik A., et al. CRH functions as a growth factor/cytokine in the skin. J Cell Physiol 206 3 (2006) 780-791
59. Slominski A., Zbytek B., Zmijewski M., et al. Corticotropin releasing hormone and the skin. Front Biosci 11 (2006) 2230-2248
60. Carlson K.W., Nawy S.S., Wei E.T., et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res 21 2A (2001) 1173-1179
61. Eberle J., Weitmann S., Thieck O., et al. Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 112 6 (1999) 925-932
62. Rosano L., Spinella F., Genovesi G., et al. Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression. J Cardiovasc Pharmacol 44 (2004) S136-S139
63. Berger Y., Bernasconi C.C., and Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) 231 6 (2006) 1111-1119
64. Slominski A., Pisarchik A., Zbytek B., et al. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol 196 1 (2003) 144-153
65. Fisher T., Zmijewski M., Zbytek B., et al. Oncostatic effects of indole melatonin and expression of its cytosolic and nuclear receptor in cultured human melanoma cell lines. Int J Oncol 29 (2006) 665-672
66. Slominski A., Pisarchik A., Semak I., et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J 16 8 (2002) 896-898
67. Slominski A., Semak I., Pisarchik A., et al. Conversion of L-tryptophan to serotonin and melatonin in melanoma cells. FEBS Lett 511 (2002) 102-106
68. Weeraratna A.T. A Wnt-er wonderland-the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev 24 2 (2005) 237-250
69. Bittner M., Meltzer P., Chen Y., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406 6795 (2000) 536-540
70. Pham K., Milovanovic T., Barr R.J., et al. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol 56 5 (2003) 280-285
71. Namkoong J., Martino J.J., and Chen S. From existing therapies to novel targets: a current view on melanoma. Front Biosci 11 (2006) 2081-2092
72. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 250 2 (2001) 91-104
73. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201 8 (2005) 1307-1318
74. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001) 50-56
75. Murakami T., Maki W., Cardones A.R., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62 24 (2002) 7328-7334
76. Scala S., Ottaiano A., Ascierto P.A., et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11 5 (2005) 1835-1841
77. Scala S., Giuliano P., Ascierto P.A., et al. Human melanoma metastases express functional CXCR4. Clin Cancer Res 12 8 (2006) 2427-2433
78. Alexeev V., and Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126 5 (2006) 1102-1110
79. Wyman K., Atkins M.B., Prieto V., et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106 9 (2006) 2005-2011
80. Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol 8 2 (2006) 77-82
81. Simonetti O., Lucarini G., Brancorsini D., et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95 9 (2002) 1963-1970
82. Graells J., Vinyals A., Figueras A., et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123 6 (2004) 1151-1161
83. Adnane L., Trail P.A., Taylor I., et al. Sorafenib (BAY 43-9006, Nexavar((R))), a Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods Enzymol 407 (2005) 597-612
84. Sharma V., Kaur I., and Kumar B. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. Int J Dermatol 42 10 (2003) 834-838
85. Flaherty K.T., Brose M., Schuchter L., et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22 14S (2004) 7507
86. Flaherty K.T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 12 7 Pt 2 (2006) 2366s-2370s
87. Bouralexis S., Findlay D.M., and Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10 1 (2005) 35-51
88. McCarthy M.M., Divito K.A., Sznol M., et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 12 12 (2006) 3856-3863
89. Kurbanov B.M., Geilen C.C., Fecker L.F., et al. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 125 5 (2005) 1010-1019
90. Fischer U., and Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 12 Suppl 1 (2005) 942-961
91. Blank C., Kuball J., Voelkl S., et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119 2 (2006) 317-327
92. Wu J.J., Zhang X.D., Gillespie S., et al. Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Lett 579 9 (2005) 1940-1944
93. Zhang X.D., Franco A., Myers K., et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59 11 (1999) 2747-2753
94. Redondo P., Solano T., Vazquez B., et al. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma. Br J Dermatol 147 1 (2002) 80-86
95. Shin M.S., Park W.S., Kim S.Y., et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 154 6 (1999) 1785-1791
96. Eberle A.N., and Froidevaux S. Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit 16 5 (2003) 248-254
97. Haass N.K., Smalley K.S., Li L., et al. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 18 3 (2005) 150-159
98. Bissell M.J., Radisky D.C., Rizki A., et al. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70 9-10 (2002) 537-546
99. Ruiter D., Bogenrieder T., Elder D., et al. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 3 1 (2002) 35-43
100. Aplin A.E., Howe A., Alahari S.K., et al. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 50 2 (1998) 197-263
101. Hsu M., Andl T., Li G., et al. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 113 Pt 9 (2000) 1535-1542
102. Hsu M.Y., Wheelock M.J., Johnson K.R., et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1 2 (1996) 188-194
103. Albelda S.M., Mette S.A., Elder D.E., et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50 20 (1990) 6757-6764
104. Woods D., Cherwinski H., Venetsanakos E., et al. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 21 9 (2001) 3192-3205
105. Haubner R., Wester H.J., Burkhart F., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42 2 (2001) 326-336
106. Eskens F.A., Dumez H., Hoekstra R., et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39 7 (2003) 917-926
107. McGary E.C., Lev D.C., and Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 1 5 (2002) 459-465
108. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296 5577 (2002) 2404-2407
109. Lehmann J.M., Riethmuller G., and Johnson J.P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 86 24 (1989) 9891-9895
110. Shih I.M., Elder D.E., Hsu M.Y., et al. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 145 4 (1994) 837-845
111. Shih I.M., Elder D.E., Speicher D., et al. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 54 9 (1994) 2514-2520
112. Satyamoorthy K., Muyrers J., Meier F., et al. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 20 34 (2001) 4676-4684
113. Xie S., Luca M., Huang S., et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57 11 (1997) 2295-2303
114. Mills L., Tellez C., Huang S., et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62 17 (2002) 5106-5114
115. Shih I.M., Speicher D., Hsu M.Y., et al. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res 57 17 (1997) 3835-3840
116. Johnson J.P., Bar-Eli M., Jansen B., et al. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer 73 5 (1997) 769-774
117. Li G., Kalabis J., Xu X., et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 22 44 (2003) 6891-6899
118. Nickoloff B.J., Hendrix M.J., Pollock P.M., et al. Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc 10 2 (2005) 95-104
119. Nickoloff B.J., Osborne B.A., and Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22 42 (2003) 6598-6608
120. Miele L. Notch signaling. Clin Cancer Res 12 4 (2006) 1074-1079
121. Liu Z.J., Xiao M., Balint K., et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66 8 (2006) 4182-4190
122. Qin J.Z., Stennett L., Bacon P., et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 3 8 (2004) 895-902
123. Mori T., Martinez S.R., O'Day S.J., et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 66 13 (2006) 6692-6698
124. Hinrichs C.S., Palmer D.C., Rosenberg S.A., et al. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother 28 6 (2005) 517-524
125. Landi M.T., Baccarelli A., Calista D., et al. Glucocorticoid use and melanoma risk. Int J Cancer 94 2 (2001) 302-303
126. Holick M.F. Vitamin D: a millenium perspective. J Cell Biochem 88 2 (2003) 296-307
127. Holick M.F. Evolution and function of vitamin D. Recent Results Cancer Res 164 (2003) 3-28
128. Bikle D.D. Vitamin D and skin cancer. J Nutr 134 Suppl 12 (2004) 3472S-3478S
129. Bikle D.D., Oda Y., and Xie Z. Vitamin D and skin cancer: a problem in gene regulation. J Steroid Biochem Mol Biol (2005)
130. Osborne J.E., and Hutchinson P.E. Vitamin D and systemic cancer: is this relevant to malignant melanoma?. Br J Dermatol 147 2 (2002) 197-213
131. Cornwell M.L., Comstock G.W., Holick M.F., et al. Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. Photodermatol Photoimmunol Photomed 9 3 (1992) 109-112
132. Hutchinson P.E., Osborne J.E., Lear J.T., et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6 2 (2000) 498-504
133. Halsall J.A., Osborne J.E., Potter L., et al. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer 91 4 (2004) 765-770
134. Berwick M., Armstrong B.K., Ben-Porat L., et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 97 3 (2005) 195-199
135. Lim H.W., Gilchrest B.A., Cooper K.D., et al. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol 52 5 (2005) 868-876
136. Holick M.F., Garabedian M., Schnoes H.K., et al. Relationship of 25-hydroxyvitamin D3 side chain structure to biological activity. J Biol Chem 250 1 (1975) 226-230
137. Slominski A., Zjawiony J., Wortsman J., et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem 271 21 (2004) 4178-4188
138. Slominski A. Neuroendocrine system of the skin. Dermatology 211 3 (2005) 199-208
139. Slominski A., Semak I., Zjawiony J., et al. Enzymatic metabolism of ergosterol by cytochrome p450scc to biologically active 17alpha, 24-dihydroxyergosterol. Chem Biol 12 8 (2005) 931-939
140. Slominski A., Semak I., Zjawiony J., et al. The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J 272 16 (2005) 4080-4090
141. Slominski A., Semak I., Wortsman J., et al. An alternative pathway of vitamin D metabolism. FEBS J 273 13 (2006) 2891-2901